Interface Biologics
Toronto · Founded 2001
About Interface Biologics
Interface Biologics, Inc. (IBI) is a commercial stage company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices. Their patent-protected technologies include anti-thrombogenic additives for blood contacting medical devices and polymer enabled combination drug delivery devices. IBI has exclusive Endexo™ technology licensing agreements with AngioDynamics for vascular access catheters and with Fresenius Medical Care for chronic dialysis systems. AngioDynamics’ BioFlo PICCS, Ports and DuraMax Dialysis Catheter with IBI’s Endexo technology have received FDA clearance and are gaining commercial traction. IBI also has a joint venture commercial agreement with Qualimed to develop a drug-coated balloon based on IBI’s Kinesyx™ technology. The company was founded in 2001 and is headquartered in Toronto, Canada at the acclaimed MaRS Innovation Centre.
Company Facts
- Founded: 2001
- Legal name: Interface Biologics, Inc.
- Operating status: Operating
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $32.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Jan 2015)
- Website: interfacebiologics.com
- Phone: 4169771329
Social Profiles
Canonical: https://fsome.com/organization/interface-biologics-8387694 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.